GreenJay Therapeutics
Houston, US · Founded 2022 · 1 known investors
Find your way into GreenJay Therapeutics
GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.
Founders & leadership
VT
Vassil TzenovVice President & Chief Financial Officer
DP
Donald PayneCEO (deceased)
TL
Tommy LeeNamed on SEC filing
MT
Michael Thomas RedmanNamed on SEC filing
BA
Borje AnderssonNamed on SEC filing
JD
James Donald PayneNamed on SEC filing
Investors · 1
Funding
SEC filings, press & company announcements$1M disclosed across 1 of 3 rounds · 2023–2025
- Undisclosed amountSeries ADec 2025Source ↗
▶$1MofferedApr 2024 · PharmaceuticalsRule 506(b)
▶$1MofferedApr 2024 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tommy L LeeDirector
- Borje S AnderssonDirector
- Michael T RedmanDirector
- James Donald PayneExecutive Officer
- Offering amount
- $1M
- Minimum investment
- $10K
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$1MraisedJun 2023 · 27 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJun 2023 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tommy LeeDirector
- Michael Thomas RedmanExecutive Officer, Director
- Borje AnderssonDirector
- James Donald PayneExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $5K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does GreenJay Therapeutics do?
- GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.
- Who are GreenJay Therapeutics's investors?
- GreenJay Therapeutics's investors include Central Texas Angel Network.
- How much funding has GreenJay Therapeutics raised?
- GreenJay Therapeutics has disclosed $1M raised across 1 of its 3 known rounds.
- Where is GreenJay Therapeutics headquartered?
- GreenJay Therapeutics is headquartered in Houston, US.